https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-11-21 / Clin Transl Oncol 2013 Feb;15(2):95-105
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-11-21 / Clin Transl Oncol 2013 Feb;15(2):95-1052012-11-21 00:00:002019-02-15 09:17:14Radiotherapy in conjunction with superficial and intracavitary hyperthermia for the treatment of solid tumors: survival and thermal parameters
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-11-01 / Curr. Mol. Med. 2012 Nov;12(9):1183-97
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-11-01 / Curr. Mol. Med. 2012 Nov;12(9):1183-972012-11-01 00:00:002019-02-15 09:17:15Heat shock proteins (HSPs) based anti-cancer vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-11-01 / Clin. Exp. Immunol. 2012 Nov;170(2):167-77
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-11-01 / Clin. Exp. Immunol. 2012 Nov;170(2):167-772012-11-01 00:00:002019-02-15 08:50:42Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-11-01 / Gan To Kagaku Ryoho 2012 Nov;39(12):1766-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-11-01 / Gan To Kagaku Ryoho 2012 Nov;39(12):1766-92012-11-01 00:00:002012-11-01 00:00:00[Immunotherapy with hyperthermia for advanced or recurrent breast cancer patients in whom standard therapy showed no effect or was refused]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-11-01 / Oncoimmunology 2012 Nov;1(8):1401-1403
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-11-01 / Oncoimmunology 2012 Nov;1(8):1401-14032012-11-01 00:00:002019-02-15 08:39:52Targeting cancer stem cells via dendritic-cell vaccination
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-11-01 / J. Cell. Mol. Med. 2012 Nov;16(11):2827-37
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-11-01 / J. Cell. Mol. Med. 2012 Nov;16(11):2827-372012-11-01 00:00:002019-02-15 08:39:53Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-10-26 / Nutr Res 2012 Nov;32(11):873-83
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-10-26 / Nutr Res 2012 Nov;32(11):873-832012-10-26 00:00:002021-06-30 13:46:04Ascorbic acid alleviates toxicity of paclitaxel without interfering with the anticancer efficacy in mice
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-10-09 / PLoS One 2012;7(10):e46644
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-10-09 / PLoS One 2012;7(10):e466442012-10-09 00:00:002012-10-09 00:00:00Selenoprotein P status correlates to cancer-specific mortality in renal cancer patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-10-01 / Immunotherapy 2012 Oct;4(10):1011-22
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-10-01 / Immunotherapy 2012 Oct;4(10):1011-222012-10-01 00:00:002019-02-15 08:50:37Dendritic cell-based immunotherapy in mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-10-01 / Immunotherapy 2012 Oct;4(10):995-1009
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-10-01 / Immunotherapy 2012 Oct;4(10):995-10092012-10-01 00:00:002019-02-15 08:52:14Dendritic cell-based tumor vaccinations in epithelial ovarian cancer: a systematic review
